Illimis Therapeutics is a cutting-edge biotech company that is dedicated to translating the latest scientific advancements into innovative medical solutions. With a team of 28 highly skilled individuals, including 10 Ph. D.

Operating from two locations, Seoul, Korea, and Boston, USA, Illimis Therapeutics has achieved notable milestones in their research, including publications in renowned scientific journals and patent applications. Their platform technology has garnered attention, with Gaia platform patent registration in South Korea. The company has also received grants and funding, such as the 2020 Dementia Conquest Research and Development Project, TIPS Project, and an industry-academic collaborative platform project, showcasing their commitment to advancing medical research.

Illimis Therapeutics is actively involved in the scientific community, participating in conferences like AD/PD and Keystone Symposia, where they present their discoveries to a global audience. Founded in 2021, the company has raised significant funding of 342 billion KRW. Co-founded by Park Sang Hoon, CEO, and Professors Jung Won Seok and Kim Chan Hyuk from KAIST, Illimis Therapeutics is poised to make a significant impact in the field of innovative medicine